nodes	percent_of_prediction	percent_of_DWPC	metapath
Aprepitant—CYP3A4—bone cancer	0.699	1	CbGaD
Aprepitant—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00359	0.0439	CbGpPWpGaD
Aprepitant—TACR1—SIDS Susceptibility Pathways—FEV—bone cancer	0.00356	0.0435	CbGpPWpGaD
Aprepitant—CYP3A7—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00271	0.0331	CbGpPWpGaD
Aprepitant—TACR3—G alpha (q) signalling events—GRM1—bone cancer	0.00214	0.0261	CbGpPWpGaD
Aprepitant—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00196	0.0239	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00191	0.0234	CbGpPWpGaD
Aprepitant—TACR1—trigeminal nerve—bone cancer	0.00153	0.511	CbGeAlD
Aprepitant—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00151	0.0185	CbGpPWpGaD
Aprepitant—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00138	0.0169	CbGpPWpGaD
Aprepitant—TACR3—G alpha (q) signalling events—GNA11—bone cancer	0.00138	0.0168	CbGpPWpGaD
Aprepitant—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00132	0.0161	CbGpPWpGaD
Aprepitant—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00132	0.0161	CbGpPWpGaD
Aprepitant—CYP3A7—Xenobiotics—CYP3A4—bone cancer	0.00131	0.016	CbGpPWpGaD
Aprepitant—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.00126	0.0154	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—GRM4—bone cancer	0.00124	0.0152	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.00123	0.015	CbGpPWpGaD
Aprepitant—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00118	0.0144	CbGpPWpGaD
Aprepitant—CYP3A7—Metapathway biotransformation—CYP4V2—bone cancer	0.00117	0.0143	CbGpPWpGaD
Aprepitant—TACR1—cranial nerve—bone cancer	0.00109	0.364	CbGeAlD
Aprepitant—TACR3—GPCR ligand binding—GRM1—bone cancer	0.00108	0.0132	CbGpPWpGaD
Aprepitant—TACR1—G alpha (q) signalling events—GRM1—bone cancer	0.00104	0.0127	CbGpPWpGaD
Aprepitant—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000985	0.012	CbGpPWpGaD
Aprepitant—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000945	0.0116	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.000933	0.0114	CbGpPWpGaD
Aprepitant—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000911	0.0111	CbGpPWpGaD
Aprepitant—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000909	0.0111	CbGpPWpGaD
Aprepitant—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000857	0.0105	CbGpPWpGaD
Aprepitant—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000843	0.0103	CbGpPWpGaD
Aprepitant—TACR3—GPCR ligand binding—SMO—bone cancer	0.000759	0.00928	CbGpPWpGaD
Aprepitant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000746	0.00912	CbGpPWpGaD
Aprepitant—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000731	0.00894	CbGpPWpGaD
Aprepitant—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000703	0.00859	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—RGS1—bone cancer	0.000702	0.00858	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—GRM4—bone cancer	0.000702	0.00858	CbGpPWpGaD
Aprepitant—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000681	0.00832	CbGpPWpGaD
Aprepitant—TACR1—G alpha (q) signalling events—GNA11—bone cancer	0.000672	0.00822	CbGpPWpGaD
Aprepitant—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000666	0.00815	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000652	0.00797	CbGpPWpGaD
Aprepitant—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000649	0.00794	CbGpPWpGaD
Aprepitant—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000641	0.00784	CbGpPWpGaD
Aprepitant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000638	0.0078	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—GRM4—bone cancer	0.000637	0.00779	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—RGS1—bone cancer	0.000637	0.00779	CbGpPWpGaD
Aprepitant—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.00062	0.00757	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—GRM1—bone cancer	0.000609	0.00744	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—GRM4—bone cancer	0.000607	0.00742	CbGpPWpGaD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.000601	0.00735	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000594	0.00727	CbGpPWpGaD
Aprepitant—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000593	0.00725	CbGpPWpGaD
Aprepitant—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000569	0.00696	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—GRM1—bone cancer	0.000553	0.00676	CbGpPWpGaD
Aprepitant—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000548	0.0067	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—CDK4—bone cancer	0.000546	0.00667	CbGpPWpGaD
Aprepitant—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000543	0.00664	CbGpPWpGaD
Aprepitant—CYP3A7—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000536	0.00655	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—GRM1—bone cancer	0.000526	0.00643	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000508	0.00621	CbGpPWpGaD
Aprepitant—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000502	0.00614	CbGpPWpGaD
Aprepitant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000492	0.00602	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—RB1—bone cancer	0.000475	0.0058	CbGpPWpGaD
Aprepitant—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000458	0.00559	CbGpPWpGaD
Aprepitant—CYP3A7—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00044	0.00538	CbGpPWpGaD
Aprepitant—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000436	0.00533	CbGpPWpGaD
Aprepitant—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000393	0.0048	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—GNA11—bone cancer	0.000392	0.00479	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000392	0.00479	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—PTGS2—bone cancer	0.00039	0.00477	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—SMO—bone cancer	0.000389	0.00476	CbGpPWpGaD
Aprepitant—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000387	0.00474	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—GRM4—bone cancer	0.000377	0.0046	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—RGS1—bone cancer	0.000377	0.0046	CbGpPWpGaD
Aprepitant—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000372	0.00455	CbGpPWpGaD
Aprepitant—TACR1—GPCR ligand binding—SMO—bone cancer	0.000371	0.00453	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—GNA11—bone cancer	0.000356	0.00435	CbGpPWpGaD
Aprepitant—TACR3—GPCR downstream signaling—IL3—bone cancer	0.000356	0.00435	CbGpPWpGaD
Aprepitant—TACR3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.00035	0.00428	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—RGS1—bone cancer	0.000343	0.00419	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—GRM4—bone cancer	0.000343	0.00419	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—MMP9—bone cancer	0.000342	0.00418	CbGpPWpGaD
Aprepitant—Infestation NOS—Epirubicin—bone cancer	0.000333	0.00154	CcSEcCtD
Aprepitant—Infestation—Epirubicin—bone cancer	0.000333	0.00154	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00033	0.00153	CcSEcCtD
Aprepitant—Renal failure—Epirubicin—bone cancer	0.000327	0.00151	CcSEcCtD
Aprepitant—Body temperature increased—Cisplatin—bone cancer	0.000327	0.00151	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—GRM1—bone cancer	0.000326	0.00399	CbGpPWpGaD
Aprepitant—Neuropathy peripheral—Epirubicin—bone cancer	0.000326	0.00151	CcSEcCtD
Aprepitant—Stomatitis—Epirubicin—bone cancer	0.000324	0.0015	CcSEcCtD
Aprepitant—Conjunctivitis—Epirubicin—bone cancer	0.000324	0.0015	CcSEcCtD
Aprepitant—Urinary tract infection—Epirubicin—bone cancer	0.000324	0.0015	CcSEcCtD
Aprepitant—Dysuria—Doxorubicin—bone cancer	0.000323	0.00149	CcSEcCtD
Aprepitant—Neutropenia—Doxorubicin—bone cancer	0.000323	0.00149	CcSEcCtD
Aprepitant—TACR3—Signaling by GPCR—IL3—bone cancer	0.000323	0.00395	CbGpPWpGaD
Aprepitant—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000321	0.00393	CbGpPWpGaD
Aprepitant—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000321	0.00148	CcSEcCtD
Aprepitant—Pollakiuria—Doxorubicin—bone cancer	0.000319	0.00148	CcSEcCtD
Aprepitant—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000318	0.00389	CbGpPWpGaD
Aprepitant—Haematuria—Epirubicin—bone cancer	0.000317	0.00147	CcSEcCtD
Aprepitant—Pharyngitis—Methotrexate—bone cancer	0.000317	0.00147	CcSEcCtD
Aprepitant—Urinary tract disorder—Methotrexate—bone cancer	0.000315	0.00146	CcSEcCtD
Aprepitant—Photosensitivity reaction—Doxorubicin—bone cancer	0.000315	0.00146	CcSEcCtD
Aprepitant—Weight increased—Doxorubicin—bone cancer	0.000314	0.00145	CcSEcCtD
Aprepitant—Urethral disorder—Methotrexate—bone cancer	0.000313	0.00145	CcSEcCtD
Aprepitant—Weight decreased—Doxorubicin—bone cancer	0.000312	0.00145	CcSEcCtD
Aprepitant—Hyperglycaemia—Doxorubicin—bone cancer	0.000312	0.00144	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—RGS1—bone cancer	0.000311	0.00381	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—GRM4—bone cancer	0.000311	0.00381	CbGpPWpGaD
Aprepitant—Pneumonia—Doxorubicin—bone cancer	0.00031	0.00143	CcSEcCtD
Aprepitant—Infestation NOS—Doxorubicin—bone cancer	0.000308	0.00142	CcSEcCtD
Aprepitant—Infestation—Doxorubicin—bone cancer	0.000308	0.00142	CcSEcCtD
Aprepitant—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000305	0.00141	CcSEcCtD
Aprepitant—Hypersensitivity—Cisplatin—bone cancer	0.000305	0.00141	CcSEcCtD
Aprepitant—Bradycardia—Epirubicin—bone cancer	0.000304	0.00141	CcSEcCtD
Aprepitant—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000303	0.00371	CbGpPWpGaD
Aprepitant—Renal failure—Doxorubicin—bone cancer	0.000303	0.0014	CcSEcCtD
Aprepitant—Erythema multiforme—Methotrexate—bone cancer	0.000302	0.0014	CcSEcCtD
Aprepitant—Neuropathy peripheral—Doxorubicin—bone cancer	0.000302	0.0014	CcSEcCtD
Aprepitant—Stomatitis—Doxorubicin—bone cancer	0.0003	0.00139	CcSEcCtD
Aprepitant—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.0003	0.00366	CbGpPWpGaD
Aprepitant—Urinary tract infection—Doxorubicin—bone cancer	0.000299	0.00138	CcSEcCtD
Aprepitant—Conjunctivitis—Doxorubicin—bone cancer	0.000299	0.00138	CcSEcCtD
Aprepitant—Eye disorder—Methotrexate—bone cancer	0.000298	0.00138	CcSEcCtD
Aprepitant—Tinnitus—Methotrexate—bone cancer	0.000298	0.00138	CcSEcCtD
Aprepitant—Hypoaesthesia—Epirubicin—bone cancer	0.000297	0.00137	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—GRM1—bone cancer	0.000297	0.00363	CbGpPWpGaD
Aprepitant—Asthenia—Cisplatin—bone cancer	0.000297	0.00137	CcSEcCtD
Aprepitant—Pharyngitis—Epirubicin—bone cancer	0.000297	0.00137	CcSEcCtD
Aprepitant—Cardiac disorder—Methotrexate—bone cancer	0.000296	0.00137	CcSEcCtD
Aprepitant—Urinary tract disorder—Epirubicin—bone cancer	0.000295	0.00136	CcSEcCtD
Aprepitant—Haematuria—Doxorubicin—bone cancer	0.000294	0.00136	CcSEcCtD
Aprepitant—Connective tissue disorder—Epirubicin—bone cancer	0.000294	0.00136	CcSEcCtD
Aprepitant—Urethral disorder—Epirubicin—bone cancer	0.000293	0.00135	CcSEcCtD
Aprepitant—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000292	0.00358	CbGpPWpGaD
Aprepitant—Angiopathy—Methotrexate—bone cancer	0.00029	0.00134	CcSEcCtD
Aprepitant—Immune system disorder—Methotrexate—bone cancer	0.000288	0.00133	CcSEcCtD
Aprepitant—Mediastinal disorder—Methotrexate—bone cancer	0.000288	0.00133	CcSEcCtD
Aprepitant—Chills—Methotrexate—bone cancer	0.000286	0.00132	CcSEcCtD
Aprepitant—Diarrhoea—Cisplatin—bone cancer	0.000283	0.00131	CcSEcCtD
Aprepitant—Erythema multiforme—Epirubicin—bone cancer	0.000282	0.00131	CcSEcCtD
Aprepitant—Alopecia—Methotrexate—bone cancer	0.000282	0.0013	CcSEcCtD
Aprepitant—Bradycardia—Doxorubicin—bone cancer	0.000281	0.0013	CcSEcCtD
Aprepitant—TACR1—SIDS Susceptibility Pathways—JUN—bone cancer	0.000281	0.00344	CbGpPWpGaD
Aprepitant—Mental disorder—Methotrexate—bone cancer	0.00028	0.00129	CcSEcCtD
Aprepitant—Eye disorder—Epirubicin—bone cancer	0.000279	0.00129	CcSEcCtD
Aprepitant—Tinnitus—Epirubicin—bone cancer	0.000279	0.00129	CcSEcCtD
Aprepitant—Malnutrition—Methotrexate—bone cancer	0.000278	0.00129	CcSEcCtD
Aprepitant—Erythema—Methotrexate—bone cancer	0.000278	0.00129	CcSEcCtD
Aprepitant—Flushing—Epirubicin—bone cancer	0.000277	0.00128	CcSEcCtD
Aprepitant—Cardiac disorder—Epirubicin—bone cancer	0.000277	0.00128	CcSEcCtD
Aprepitant—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000277	0.00338	CbGpPWpGaD
Aprepitant—TACR1—Spinal Cord Injury—EGFR—bone cancer	0.000277	0.00338	CbGpPWpGaD
Aprepitant—Hypoaesthesia—Doxorubicin—bone cancer	0.000275	0.00127	CcSEcCtD
Aprepitant—Pharyngitis—Doxorubicin—bone cancer	0.000274	0.00127	CcSEcCtD
Aprepitant—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000273	0.00334	CbGpPWpGaD
Aprepitant—Urinary tract disorder—Doxorubicin—bone cancer	0.000273	0.00126	CcSEcCtD
Aprepitant—Dysgeusia—Methotrexate—bone cancer	0.000272	0.00126	CcSEcCtD
Aprepitant—Connective tissue disorder—Doxorubicin—bone cancer	0.000272	0.00126	CcSEcCtD
Aprepitant—Angiopathy—Epirubicin—bone cancer	0.000271	0.00125	CcSEcCtD
Aprepitant—Urethral disorder—Doxorubicin—bone cancer	0.000271	0.00125	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—GRM1—bone cancer	0.00027	0.0033	CbGpPWpGaD
Aprepitant—Immune system disorder—Epirubicin—bone cancer	0.00027	0.00125	CcSEcCtD
Aprepitant—Mediastinal disorder—Epirubicin—bone cancer	0.000269	0.00125	CcSEcCtD
Aprepitant—Back pain—Methotrexate—bone cancer	0.000269	0.00124	CcSEcCtD
Aprepitant—Chills—Epirubicin—bone cancer	0.000268	0.00124	CcSEcCtD
Aprepitant—Alopecia—Epirubicin—bone cancer	0.000264	0.00122	CcSEcCtD
Aprepitant—Vomiting—Cisplatin—bone cancer	0.000263	0.00122	CcSEcCtD
Aprepitant—Mental disorder—Epirubicin—bone cancer	0.000262	0.00121	CcSEcCtD
Aprepitant—Erythema multiforme—Doxorubicin—bone cancer	0.000261	0.00121	CcSEcCtD
Aprepitant—Rash—Cisplatin—bone cancer	0.000261	0.00121	CcSEcCtD
Aprepitant—Dermatitis—Cisplatin—bone cancer	0.00026	0.0012	CcSEcCtD
Aprepitant—Erythema—Epirubicin—bone cancer	0.00026	0.0012	CcSEcCtD
Aprepitant—Malnutrition—Epirubicin—bone cancer	0.00026	0.0012	CcSEcCtD
Aprepitant—Eye disorder—Doxorubicin—bone cancer	0.000258	0.00119	CcSEcCtD
Aprepitant—Ill-defined disorder—Methotrexate—bone cancer	0.000258	0.00119	CcSEcCtD
Aprepitant—Tinnitus—Doxorubicin—bone cancer	0.000258	0.00119	CcSEcCtD
Aprepitant—Anaemia—Methotrexate—bone cancer	0.000257	0.00119	CcSEcCtD
Aprepitant—Flushing—Doxorubicin—bone cancer	0.000257	0.00119	CcSEcCtD
Aprepitant—Cardiac disorder—Doxorubicin—bone cancer	0.000257	0.00119	CcSEcCtD
Aprepitant—Flatulence—Epirubicin—bone cancer	0.000256	0.00119	CcSEcCtD
Aprepitant—Dysgeusia—Epirubicin—bone cancer	0.000255	0.00118	CcSEcCtD
Aprepitant—Back pain—Epirubicin—bone cancer	0.000252	0.00116	CcSEcCtD
Aprepitant—Angiopathy—Doxorubicin—bone cancer	0.000251	0.00116	CcSEcCtD
Aprepitant—Malaise—Methotrexate—bone cancer	0.000251	0.00116	CcSEcCtD
Aprepitant—Muscle spasms—Epirubicin—bone cancer	0.00025	0.00116	CcSEcCtD
Aprepitant—Immune system disorder—Doxorubicin—bone cancer	0.00025	0.00115	CcSEcCtD
Aprepitant—Mediastinal disorder—Doxorubicin—bone cancer	0.000249	0.00115	CcSEcCtD
Aprepitant—Chills—Doxorubicin—bone cancer	0.000248	0.00115	CcSEcCtD
Aprepitant—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000246	0.00301	CbGpPWpGaD
Aprepitant—Nausea—Cisplatin—bone cancer	0.000246	0.00114	CcSEcCtD
Aprepitant—Alopecia—Doxorubicin—bone cancer	0.000244	0.00113	CcSEcCtD
Aprepitant—Cough—Methotrexate—bone cancer	0.000243	0.00112	CcSEcCtD
Aprepitant—Mental disorder—Doxorubicin—bone cancer	0.000242	0.00112	CcSEcCtD
Aprepitant—Ill-defined disorder—Epirubicin—bone cancer	0.000241	0.00112	CcSEcCtD
Aprepitant—Convulsion—Methotrexate—bone cancer	0.000241	0.00111	CcSEcCtD
Aprepitant—Erythema—Doxorubicin—bone cancer	0.000241	0.00111	CcSEcCtD
Aprepitant—Malnutrition—Doxorubicin—bone cancer	0.000241	0.00111	CcSEcCtD
Aprepitant—Anaemia—Epirubicin—bone cancer	0.00024	0.00111	CcSEcCtD
Aprepitant—Flatulence—Doxorubicin—bone cancer	0.000237	0.0011	CcSEcCtD
Aprepitant—Myalgia—Methotrexate—bone cancer	0.000237	0.00109	CcSEcCtD
Aprepitant—Arthralgia—Methotrexate—bone cancer	0.000237	0.00109	CcSEcCtD
Aprepitant—Chest pain—Methotrexate—bone cancer	0.000237	0.00109	CcSEcCtD
Aprepitant—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000236	0.00289	CbGpPWpGaD
Aprepitant—Dysgeusia—Doxorubicin—bone cancer	0.000236	0.00109	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000235	0.00109	CcSEcCtD
Aprepitant—Malaise—Epirubicin—bone cancer	0.000235	0.00108	CcSEcCtD
Aprepitant—CYP3A7—Biological oxidations—CYP3A4—bone cancer	0.000234	0.00286	CbGpPWpGaD
Aprepitant—Discomfort—Methotrexate—bone cancer	0.000234	0.00108	CcSEcCtD
Aprepitant—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000233	0.00285	CbGpPWpGaD
Aprepitant—Syncope—Epirubicin—bone cancer	0.000233	0.00108	CcSEcCtD
Aprepitant—Back pain—Doxorubicin—bone cancer	0.000233	0.00108	CcSEcCtD
Aprepitant—TACR1—Spinal Cord Injury—TP53—bone cancer	0.000232	0.00284	CbGpPWpGaD
Aprepitant—Muscle spasms—Doxorubicin—bone cancer	0.000231	0.00107	CcSEcCtD
Aprepitant—CYP3A7—Metapathway biotransformation—CYP3A4—bone cancer	0.000231	0.00282	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—SMO—bone cancer	0.00023	0.00281	CbGpPWpGaD
Aprepitant—Palpitations—Epirubicin—bone cancer	0.00023	0.00106	CcSEcCtD
Aprepitant—Confusional state—Methotrexate—bone cancer	0.000229	0.00106	CcSEcCtD
Aprepitant—Loss of consciousness—Epirubicin—bone cancer	0.000229	0.00106	CcSEcCtD
Aprepitant—Cough—Epirubicin—bone cancer	0.000227	0.00105	CcSEcCtD
Aprepitant—Anaphylactic shock—Methotrexate—bone cancer	0.000227	0.00105	CcSEcCtD
Aprepitant—Convulsion—Epirubicin—bone cancer	0.000225	0.00104	CcSEcCtD
Aprepitant—Infection—Methotrexate—bone cancer	0.000225	0.00104	CcSEcCtD
Aprepitant—TACR1—connective tissue—bone cancer	0.000225	0.0751	CbGeAlD
Aprepitant—Hypertension—Epirubicin—bone cancer	0.000225	0.00104	CcSEcCtD
Aprepitant—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000224	0.00274	CbGpPWpGaD
Aprepitant—Ill-defined disorder—Doxorubicin—bone cancer	0.000223	0.00103	CcSEcCtD
Aprepitant—Nervous system disorder—Methotrexate—bone cancer	0.000222	0.00103	CcSEcCtD
Aprepitant—Anaemia—Doxorubicin—bone cancer	0.000222	0.00103	CcSEcCtD
Aprepitant—Thrombocytopenia—Methotrexate—bone cancer	0.000222	0.00103	CcSEcCtD
Aprepitant—Myalgia—Epirubicin—bone cancer	0.000221	0.00102	CcSEcCtD
Aprepitant—Chest pain—Epirubicin—bone cancer	0.000221	0.00102	CcSEcCtD
Aprepitant—Arthralgia—Epirubicin—bone cancer	0.000221	0.00102	CcSEcCtD
Aprepitant—Anxiety—Epirubicin—bone cancer	0.000221	0.00102	CcSEcCtD
Aprepitant—Skin disorder—Methotrexate—bone cancer	0.00022	0.00102	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00022	0.00102	CcSEcCtD
Aprepitant—Hyperhidrosis—Methotrexate—bone cancer	0.000219	0.00101	CcSEcCtD
Aprepitant—Discomfort—Epirubicin—bone cancer	0.000219	0.00101	CcSEcCtD
Aprepitant—Malaise—Doxorubicin—bone cancer	0.000217	0.001	CcSEcCtD
Aprepitant—Dry mouth—Epirubicin—bone cancer	0.000217	0.001	CcSEcCtD
Aprepitant—Anorexia—Methotrexate—bone cancer	0.000216	0.001	CcSEcCtD
Aprepitant—Syncope—Doxorubicin—bone cancer	0.000216	0.000998	CcSEcCtD
Aprepitant—Confusional state—Epirubicin—bone cancer	0.000214	0.00099	CcSEcCtD
Aprepitant—Palpitations—Doxorubicin—bone cancer	0.000213	0.000984	CcSEcCtD
Aprepitant—Anaphylactic shock—Epirubicin—bone cancer	0.000212	0.000982	CcSEcCtD
Aprepitant—Oedema—Epirubicin—bone cancer	0.000212	0.000982	CcSEcCtD
Aprepitant—Hypotension—Methotrexate—bone cancer	0.000212	0.00098	CcSEcCtD
Aprepitant—Loss of consciousness—Doxorubicin—bone cancer	0.000212	0.000978	CcSEcCtD
Aprepitant—Infection—Epirubicin—bone cancer	0.000211	0.000975	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—GNA11—bone cancer	0.00021	0.00257	CbGpPWpGaD
Aprepitant—Cough—Doxorubicin—bone cancer	0.00021	0.000971	CcSEcCtD
Aprepitant—Shock—Epirubicin—bone cancer	0.000209	0.000966	CcSEcCtD
Aprepitant—Convulsion—Doxorubicin—bone cancer	0.000209	0.000964	CcSEcCtD
Aprepitant—Nervous system disorder—Epirubicin—bone cancer	0.000208	0.000963	CcSEcCtD
Aprepitant—Thrombocytopenia—Epirubicin—bone cancer	0.000208	0.000961	CcSEcCtD
Aprepitant—Hypertension—Doxorubicin—bone cancer	0.000208	0.000961	CcSEcCtD
Aprepitant—Tachycardia—Epirubicin—bone cancer	0.000207	0.000958	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000207	0.000956	CcSEcCtD
Aprepitant—Skin disorder—Epirubicin—bone cancer	0.000206	0.000954	CcSEcCtD
Aprepitant—Hyperhidrosis—Epirubicin—bone cancer	0.000205	0.000949	CcSEcCtD
Aprepitant—Insomnia—Methotrexate—bone cancer	0.000205	0.000949	CcSEcCtD
Aprepitant—Chest pain—Doxorubicin—bone cancer	0.000205	0.000947	CcSEcCtD
Aprepitant—Myalgia—Doxorubicin—bone cancer	0.000205	0.000947	CcSEcCtD
Aprepitant—Arthralgia—Doxorubicin—bone cancer	0.000205	0.000947	CcSEcCtD
Aprepitant—Anxiety—Doxorubicin—bone cancer	0.000204	0.000944	CcSEcCtD
Aprepitant—Paraesthesia—Methotrexate—bone cancer	0.000204	0.000942	CcSEcCtD
Aprepitant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000203	0.000941	CcSEcCtD
Aprepitant—Discomfort—Doxorubicin—bone cancer	0.000202	0.000936	CcSEcCtD
Aprepitant—Anorexia—Epirubicin—bone cancer	0.000202	0.000936	CcSEcCtD
Aprepitant—Dyspnoea—Methotrexate—bone cancer	0.000202	0.000935	CcSEcCtD
Aprepitant—Somnolence—Methotrexate—bone cancer	0.000202	0.000933	CcSEcCtD
Aprepitant—Dry mouth—Doxorubicin—bone cancer	0.0002	0.000927	CcSEcCtD
Aprepitant—CYP3A7—Biological oxidations—GSTP1—bone cancer	0.0002	0.00245	CbGpPWpGaD
Aprepitant—Dyspepsia—Methotrexate—bone cancer	0.0002	0.000923	CcSEcCtD
Aprepitant—Hypotension—Epirubicin—bone cancer	0.000198	0.000917	CcSEcCtD
Aprepitant—Confusional state—Doxorubicin—bone cancer	0.000198	0.000916	CcSEcCtD
Aprepitant—CYP3A7—Metapathway biotransformation—GSTP1—bone cancer	0.000197	0.00241	CbGpPWpGaD
Aprepitant—Decreased appetite—Methotrexate—bone cancer	0.000197	0.000912	CcSEcCtD
Aprepitant—Anaphylactic shock—Doxorubicin—bone cancer	0.000196	0.000908	CcSEcCtD
Aprepitant—Oedema—Doxorubicin—bone cancer	0.000196	0.000908	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Methotrexate—bone cancer	0.000196	0.000906	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—ATF1—bone cancer	0.000196	0.00239	CbGpPWpGaD
Aprepitant—Fatigue—Methotrexate—bone cancer	0.000196	0.000904	CcSEcCtD
Aprepitant—Infection—Doxorubicin—bone cancer	0.000195	0.000902	CcSEcCtD
Aprepitant—Pain—Methotrexate—bone cancer	0.000194	0.000897	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000193	0.000894	CcSEcCtD
Aprepitant—Shock—Doxorubicin—bone cancer	0.000193	0.000894	CcSEcCtD
Aprepitant—Nervous system disorder—Doxorubicin—bone cancer	0.000193	0.000891	CcSEcCtD
Aprepitant—Thrombocytopenia—Doxorubicin—bone cancer	0.000192	0.000889	CcSEcCtD
Aprepitant—Insomnia—Epirubicin—bone cancer	0.000192	0.000888	CcSEcCtD
Aprepitant—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000192	0.00234	CbGpPWpGaD
Aprepitant—Tachycardia—Doxorubicin—bone cancer	0.000192	0.000886	CcSEcCtD
Aprepitant—TACR1—GPCR downstream signaling—GNA11—bone cancer	0.000192	0.00234	CbGpPWpGaD
Aprepitant—Skin disorder—Doxorubicin—bone cancer	0.000191	0.000882	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—IL3—bone cancer	0.000191	0.00233	CbGpPWpGaD
Aprepitant—Paraesthesia—Epirubicin—bone cancer	0.000191	0.000881	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—SMO—bone cancer	0.00019	0.00232	CbGpPWpGaD
Aprepitant—Hyperhidrosis—Doxorubicin—bone cancer	0.00019	0.000878	CcSEcCtD
Aprepitant—Dyspnoea—Epirubicin—bone cancer	0.000189	0.000875	CcSEcCtD
Aprepitant—Somnolence—Epirubicin—bone cancer	0.000189	0.000873	CcSEcCtD
Aprepitant—Anorexia—Doxorubicin—bone cancer	0.000187	0.000866	CcSEcCtD
Aprepitant—Feeling abnormal—Methotrexate—bone cancer	0.000187	0.000864	CcSEcCtD
Aprepitant—Dyspepsia—Epirubicin—bone cancer	0.000187	0.000864	CcSEcCtD
Aprepitant—Gastrointestinal pain—Methotrexate—bone cancer	0.000185	0.000858	CcSEcCtD
Aprepitant—Decreased appetite—Epirubicin—bone cancer	0.000185	0.000853	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—GRM4—bone cancer	0.000184	0.00225	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—RGS1—bone cancer	0.000184	0.00225	CbGpPWpGaD
Aprepitant—Hypotension—Doxorubicin—bone cancer	0.000184	0.000849	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Epirubicin—bone cancer	0.000183	0.000847	CcSEcCtD
Aprepitant—Fatigue—Epirubicin—bone cancer	0.000183	0.000846	CcSEcCtD
Aprepitant—Pain—Epirubicin—bone cancer	0.000182	0.000839	CcSEcCtD
Aprepitant—Constipation—Epirubicin—bone cancer	0.000182	0.000839	CcSEcCtD
Aprepitant—Urticaria—Methotrexate—bone cancer	0.00018	0.000833	CcSEcCtD
Aprepitant—Body temperature increased—Methotrexate—bone cancer	0.000179	0.000829	CcSEcCtD
Aprepitant—Abdominal pain—Methotrexate—bone cancer	0.000179	0.000829	CcSEcCtD
Aprepitant—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000179	0.000828	CcSEcCtD
Aprepitant—Insomnia—Doxorubicin—bone cancer	0.000178	0.000822	CcSEcCtD
Aprepitant—Paraesthesia—Doxorubicin—bone cancer	0.000176	0.000816	CcSEcCtD
Aprepitant—Dyspnoea—Doxorubicin—bone cancer	0.000175	0.00081	CcSEcCtD
Aprepitant—Feeling abnormal—Epirubicin—bone cancer	0.000175	0.000809	CcSEcCtD
Aprepitant—Somnolence—Doxorubicin—bone cancer	0.000175	0.000807	CcSEcCtD
Aprepitant—TACR1—Signaling by GPCR—GNA11—bone cancer	0.000174	0.00213	CbGpPWpGaD
Aprepitant—TACR1—GPCR downstream signaling—IL3—bone cancer	0.000174	0.00212	CbGpPWpGaD
Aprepitant—Gastrointestinal pain—Epirubicin—bone cancer	0.000174	0.000803	CcSEcCtD
Aprepitant—Dyspepsia—Doxorubicin—bone cancer	0.000173	0.0008	CcSEcCtD
Aprepitant—TACR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000171	0.00209	CbGpPWpGaD
Aprepitant—Decreased appetite—Doxorubicin—bone cancer	0.000171	0.00079	CcSEcCtD
Aprepitant—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00017	0.000784	CcSEcCtD
Aprepitant—Fatigue—Doxorubicin—bone cancer	0.000169	0.000783	CcSEcCtD
Aprepitant—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000169	0.00207	CbGpPWpGaD
Aprepitant—Urticaria—Epirubicin—bone cancer	0.000169	0.00078	CcSEcCtD
Aprepitant—Pain—Doxorubicin—bone cancer	0.000168	0.000777	CcSEcCtD
Aprepitant—Constipation—Doxorubicin—bone cancer	0.000168	0.000777	CcSEcCtD
Aprepitant—Body temperature increased—Epirubicin—bone cancer	0.000168	0.000776	CcSEcCtD
Aprepitant—Abdominal pain—Epirubicin—bone cancer	0.000168	0.000776	CcSEcCtD
Aprepitant—Hypersensitivity—Methotrexate—bone cancer	0.000167	0.000773	CcSEcCtD
Aprepitant—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000167	0.00204	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TGFBR2—bone cancer	0.000163	0.00199	CbGpPWpGaD
Aprepitant—Asthenia—Methotrexate—bone cancer	0.000163	0.000753	CcSEcCtD
Aprepitant—Feeling abnormal—Doxorubicin—bone cancer	0.000162	0.000748	CcSEcCtD
Aprepitant—Gastrointestinal pain—Doxorubicin—bone cancer	0.000161	0.000743	CcSEcCtD
Aprepitant—Pruritus—Methotrexate—bone cancer	0.00016	0.000742	CcSEcCtD
Aprepitant—TACR1—Signaling Pathways—GRM1—bone cancer	0.000159	0.00195	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—IL3—bone cancer	0.000158	0.00193	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000158	0.00193	CbGpPWpGaD
Aprepitant—Hypersensitivity—Epirubicin—bone cancer	0.000156	0.000723	CcSEcCtD
Aprepitant—Urticaria—Doxorubicin—bone cancer	0.000156	0.000722	CcSEcCtD
Aprepitant—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000156	0.0019	CbGpPWpGaD
Aprepitant—Body temperature increased—Doxorubicin—bone cancer	0.000155	0.000718	CcSEcCtD
Aprepitant—Abdominal pain—Doxorubicin—bone cancer	0.000155	0.000718	CcSEcCtD
Aprepitant—Diarrhoea—Methotrexate—bone cancer	0.000155	0.000718	CcSEcCtD
Aprepitant—TACR3—Signaling Pathways—IGF1R—bone cancer	0.000153	0.00188	CbGpPWpGaD
Aprepitant—Asthenia—Epirubicin—bone cancer	0.000152	0.000704	CcSEcCtD
Aprepitant—Pruritus—Epirubicin—bone cancer	0.00015	0.000695	CcSEcCtD
Aprepitant—Dizziness—Methotrexate—bone cancer	0.00015	0.000694	CcSEcCtD
Aprepitant—TACR1—spinal cord—bone cancer	0.000149	0.0498	CbGeAlD
Aprepitant—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000149	0.00182	CbGpPWpGaD
Aprepitant—Diarrhoea—Epirubicin—bone cancer	0.000145	0.000672	CcSEcCtD
Aprepitant—Hypersensitivity—Doxorubicin—bone cancer	0.000145	0.000669	CcSEcCtD
Aprepitant—CYP3A5—Biological oxidations—GSTP1—bone cancer	0.000145	0.00177	CbGpPWpGaD
Aprepitant—Vomiting—Methotrexate—bone cancer	0.000144	0.000667	CcSEcCtD
Aprepitant—Rash—Methotrexate—bone cancer	0.000143	0.000661	CcSEcCtD
Aprepitant—Dermatitis—Methotrexate—bone cancer	0.000143	0.000661	CcSEcCtD
Aprepitant—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.000143	0.00174	CbGpPWpGaD
Aprepitant—Headache—Methotrexate—bone cancer	0.000142	0.000657	CcSEcCtD
Aprepitant—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	0.000142	0.00173	CbGpPWpGaD
Aprepitant—Asthenia—Doxorubicin—bone cancer	0.000141	0.000652	CcSEcCtD
Aprepitant—Dizziness—Epirubicin—bone cancer	0.00014	0.000649	CcSEcCtD
Aprepitant—CYP3A7—Metabolism—NDUFA12—bone cancer	0.00014	0.00171	CbGpPWpGaD
Aprepitant—Pruritus—Doxorubicin—bone cancer	0.000139	0.000643	CcSEcCtD
Aprepitant—Vomiting—Epirubicin—bone cancer	0.000135	0.000624	CcSEcCtD
Aprepitant—Nausea—Methotrexate—bone cancer	0.000135	0.000623	CcSEcCtD
Aprepitant—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000134	0.00164	CbGpPWpGaD
Aprepitant—Diarrhoea—Doxorubicin—bone cancer	0.000134	0.000621	CcSEcCtD
Aprepitant—Rash—Epirubicin—bone cancer	0.000134	0.000619	CcSEcCtD
Aprepitant—Dermatitis—Epirubicin—bone cancer	0.000134	0.000618	CcSEcCtD
Aprepitant—Headache—Epirubicin—bone cancer	0.000133	0.000615	CcSEcCtD
Aprepitant—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.000131	0.0016	CbGpPWpGaD
Aprepitant—Dizziness—Doxorubicin—bone cancer	0.00013	0.000601	CcSEcCtD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.00013	0.00158	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000129	0.00158	CbGpPWpGaD
Aprepitant—Nausea—Epirubicin—bone cancer	0.000126	0.000583	CcSEcCtD
Aprepitant—Vomiting—Doxorubicin—bone cancer	0.000125	0.000578	CcSEcCtD
Aprepitant—Rash—Doxorubicin—bone cancer	0.000124	0.000573	CcSEcCtD
Aprepitant—Dermatitis—Doxorubicin—bone cancer	0.000124	0.000572	CcSEcCtD
Aprepitant—Headache—Doxorubicin—bone cancer	0.000123	0.000569	CcSEcCtD
Aprepitant—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000121	0.00148	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—CYP3A4—bone cancer	0.000119	0.00146	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	0.000118	0.00144	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000117	0.00143	CbGpPWpGaD
Aprepitant—Nausea—Doxorubicin—bone cancer	0.000117	0.00054	CcSEcCtD
Aprepitant—CYP3A7—Metabolism—NT5C3A—bone cancer	0.000116	0.00142	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—SMO—bone cancer	0.000112	0.00137	CbGpPWpGaD
Aprepitant—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000112	0.00137	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—KIT—bone cancer	0.000111	0.00136	CbGpPWpGaD
Aprepitant—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.00011	0.00135	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—BRAF—bone cancer	0.000105	0.00128	CbGpPWpGaD
Aprepitant—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000104	0.00127	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—GNA11—bone cancer	0.000103	0.00126	CbGpPWpGaD
Aprepitant—CYP2C9—Biological oxidations—GSTP1—bone cancer	0.000102	0.00125	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000102	0.00124	CbGpPWpGaD
Aprepitant—TACR3—Signaling by GPCR—EGFR—bone cancer	0.000101	0.00124	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NDUFA12—bone cancer	0.000101	0.00124	CbGpPWpGaD
Aprepitant—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	0.000101	0.00123	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.0001	0.00123	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—ATF1—bone cancer	9.55e-05	0.00117	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IL3—bone cancer	9.32e-05	0.00114	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	9.19e-05	0.00112	CbGpPWpGaD
Aprepitant—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	9.19e-05	0.00112	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MDM2—bone cancer	8.77e-05	0.00107	CbGpPWpGaD
Aprepitant—CYP1A2—Biological oxidations—GSTP1—bone cancer	8.71e-05	0.00106	CbGpPWpGaD
Aprepitant—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	8.59e-05	0.00105	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—NT5C3A—bone cancer	8.4e-05	0.00103	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TGFBR2—bone cancer	7.97e-05	0.000974	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NDUFA12—bone cancer	7.83e-05	0.000958	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—JUN—bone cancer	7.62e-05	0.000932	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—IGF1R—bone cancer	7.5e-05	0.000916	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—MMP9—bone cancer	7.41e-05	0.000906	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NDUFA12—bone cancer	7.14e-05	0.000873	CbGpPWpGaD
Aprepitant—CYP3A4—Biological oxidations—GSTP1—bone cancer	6.72e-05	0.000822	CbGpPWpGaD
Aprepitant—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	6.63e-05	0.00081	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—NT5C3A—bone cancer	6.49e-05	0.000794	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NDUFA12—bone cancer	6.1e-05	0.000746	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—EGFR—bone cancer	5.99e-05	0.000732	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—NT5C3A—bone cancer	5.92e-05	0.000724	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—KIT—bone cancer	5.44e-05	0.000665	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—BRAF—bone cancer	5.11e-05	0.000625	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—ENO2—bone cancer	5.09e-05	0.000622	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—NT5C3A—bone cancer	5.06e-05	0.000618	CbGpPWpGaD
Aprepitant—TACR3—Signaling Pathways—TP53—bone cancer	5.03e-05	0.000615	CbGpPWpGaD
Aprepitant—TACR1—Signaling by GPCR—EGFR—bone cancer	4.95e-05	0.000606	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—DHFR—bone cancer	4.72e-05	0.000577	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NDUFA12—bone cancer	4.71e-05	0.000576	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GNA11—bone cancer	4.41e-05	0.000539	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MDM2—bone cancer	4.28e-05	0.000523	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—CYP3A4—bone cancer	4e-05	0.000489	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—NT5C3A—bone cancer	3.9e-05	0.000477	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—JUN—bone cancer	3.72e-05	0.000455	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—ENO2—bone cancer	3.68e-05	0.00045	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—MMP9—bone cancer	3.62e-05	0.000443	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—GSTP1—bone cancer	3.42e-05	0.000418	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—DHFR—bone cancer	3.41e-05	0.000417	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GNA11—bone cancer	3.19e-05	0.00039	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—EGFR—bone cancer	2.93e-05	0.000358	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—CYP3A4—bone cancer	2.89e-05	0.000353	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—ENO2—bone cancer	2.84e-05	0.000348	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—DHFR—bone cancer	2.64e-05	0.000322	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—ENO2—bone cancer	2.59e-05	0.000317	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—GSTP1—bone cancer	2.47e-05	0.000302	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GNA11—bone cancer	2.47e-05	0.000301	CbGpPWpGaD
Aprepitant—TACR1—Signaling Pathways—TP53—bone cancer	2.46e-05	0.0003	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—DHFR—bone cancer	2.41e-05	0.000294	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GNA11—bone cancer	2.25e-05	0.000275	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—CYP3A4—bone cancer	2.24e-05	0.000273	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.22e-05	0.000272	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—ENO2—bone cancer	2.22e-05	0.000271	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—DHFR—bone cancer	2.06e-05	0.000251	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—CYP3A4—bone cancer	2.04e-05	0.000249	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.03e-05	0.000248	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GNA11—bone cancer	1.92e-05	0.000235	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—GSTP1—bone cancer	1.91e-05	0.000234	CbGpPWpGaD
Aprepitant—CYP3A7—Metabolism—PTGS2—bone cancer	1.77e-05	0.000217	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—GSTP1—bone cancer	1.74e-05	0.000213	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—CYP3A4—bone cancer	1.74e-05	0.000213	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.73e-05	0.000212	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—ENO2—bone cancer	1.71e-05	0.000209	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—DHFR—bone cancer	1.59e-05	0.000194	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—GSTP1—bone cancer	1.49e-05	0.000182	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GNA11—bone cancer	1.48e-05	0.000181	CbGpPWpGaD
Aprepitant—CYP3A5—Metabolism—PTGS2—bone cancer	1.28e-05	0.000157	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—GSTP1—bone cancer	1.15e-05	0.000141	CbGpPWpGaD
Aprepitant—CYP2C19—Metabolism—PTGS2—bone cancer	9.9e-06	0.000121	CbGpPWpGaD
Aprepitant—CYP2C9—Metabolism—PTGS2—bone cancer	9.03e-06	0.00011	CbGpPWpGaD
Aprepitant—CYP1A2—Metabolism—PTGS2—bone cancer	7.72e-06	9.43e-05	CbGpPWpGaD
Aprepitant—CYP3A4—Metabolism—PTGS2—bone cancer	5.96e-06	7.28e-05	CbGpPWpGaD
